NCT05044819 2026-04-22
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Jazz Pharmaceuticals
Phase 4 Active not recruiting
Clinical Trials
12 trialsNCT06533657 2026-04-21
UTOPIA-1
ZYUS Life Sciences Inc.
Phase 2 Completed
NCT06538389 2026-04-15
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
Phase 2 Suspended
NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
NCT05864846 2026-03-12
EpiCom
Jazz Pharmaceuticals
Phase 4 Active not recruiting
NCT05388058 2026-01-16
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Mayo Clinic
Phase 2 Completed
NCT06731894 2025-12-05
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
City of Hope Medical Center
Phase 2 Recruiting
NCT04485104 2025-10-31
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
Jazz Pharmaceuticals
Phase 3 Terminated
NCT07167446 2025-10-22
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
Fox Chase Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT03948074 2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2 Completed
NCT04482244 2025-07-29
RCT of CBD for Anxiety in Advanced Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04754399 2025-05-09
Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
University of Michigan Rogel Cancer Center
Phase 2 Completed